JPMorgan raised the firm’s price target on CG Oncology (CGON) to $47 from $41 and keeps an Overweight rating on the shares. The firm rolled forward its price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Biotech Alert: Searches spiking for these stocks today
- CG Oncology price target raised to $79 from $56 at Morgan Stanley
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Buy Rating for CG Oncology: Creto’s Market Potential and Strategic Pricing Flexibility
- CG Oncology Highlights Drug Potential at Healthcare Conference